2015
DOI: 10.4172/2155-6180.1000263
|View full text |Cite
|
Sign up to set email alerts
|

Bayesian Estimation of the Three Key Parameters in CT for the National Lung Screening Trial Data

Abstract: In this study cancer screening likelihood method was used to analyze the CT scan group in the National Lung Screening Trial (NLST) data. Three key parameters: screening sensitivity, transition probability density from disease free to preclinical state, and sojourn time in the preclinical state, were estimated using Bayesian approach and Markov Chain Monte Carlo simulations. The sensitivity for lung cancer screening using CT scan is high; it does not depend on a patient's age, and is slightly higher in females … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
2
0

Year Published

2017
2017
2021
2021

Publication Types

Select...
5
1

Relationship

1
5

Authors

Journals

citations
Cited by 6 publications
(3 citation statements)
references
References 8 publications
0
2
0
Order By: Relevance
“…[10] Wu et al demonstrated that the 95% highest posterior density (HPD) interval for sensitivity is (0.72, 0.98) with a posterior mean 0.89 on the Mayo Lung Project. [7] The sensitivity estimated in the study of Liu et al [11] using the NLST low dose CT group data was around 0.95 for all male-female groups, confirming that low dose CT scan improves lung cancer screening sensitivity greatly. Three previous studies had reported sensitivity of chest X-ray and that had a low risk of bias and, the sensitivity estimates for these studies were: 79.3% (95% CI = 67.6 to 91.0%), 76.8% (95% CI = 64.5 to 84.2%), and 79.7% (95% CI = 72.7 to 86.8%).…”
Section: Discussionmentioning
confidence: 76%
“…[10] Wu et al demonstrated that the 95% highest posterior density (HPD) interval for sensitivity is (0.72, 0.98) with a posterior mean 0.89 on the Mayo Lung Project. [7] The sensitivity estimated in the study of Liu et al [11] using the NLST low dose CT group data was around 0.95 for all male-female groups, confirming that low dose CT scan improves lung cancer screening sensitivity greatly. Three previous studies had reported sensitivity of chest X-ray and that had a low risk of bias and, the sensitivity estimates for these studies were: 79.3% (95% CI = 67.6 to 91.0%), 76.8% (95% CI = 64.5 to 84.2%), and 79.7% (95% CI = 72.7 to 86.8%).…”
Section: Discussionmentioning
confidence: 76%
“…and the same parametric models for the w(t), q(x) and Q(x) as in Equations ( 14)- (16). The six unknown parameters θ = (b 0 , b 1 , μ, σ 2 , λ, α) were estimated using Markov Chain Monte Carlo (MCMC) and a likelihood function based on the NLST-LDCT data [22]: two Markov Chains were simulated with overdispersed initial values. Each chain ran 130,000 iterations, with 30,000 burn-in steps; after the burn-in, the posteriors were sampled every 200 steps, providing 500 posteriors θ * from each chain.…”
Section: Applicationmentioning
confidence: 99%
“…Although our proposed non-standard case-cohort design can be applied to any continuous-time Markov process with states defined by each study, for the ease of presentation without loss of generality, the conventional three-state Markov model is applied to elucidating the multistate natural history of BC and CRC, commencing from the disease-free status (state 0), asymptomatic status without clinical symptom but can be detected by the screening method (state 1) defined as the preclinical detectable phase (PCDP), and symptomatic status showing clinical symptoms and signs (state 2) defined as the clinical phase (CP). While the proposed Markov processes were applied to population-based screening data as shown in several our and other previous studies, 7,8,11,2227 they should be calibrated to accommodate three major issues, including censoring, truncation related to length-bias, and imperfect sensitivity. Lacking of calibration for these issues often led to biased estimates even when a sampling-based Markov process is applied.…”
Section: Markov Process For Population-based Screening Datamentioning
confidence: 99%